Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Clinical Nuclear Medicine
|
August 15, 2017
PET/CT in an 8-Year-Old Girl With Epstein-Barr Virus-Associated Smooth Muscle Tumor
Ishan Garg, Maria J Baladron Zanetti, Saba Yasir, et al.
Clinical Nuclear Medicine
|
October 9, 2015
Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver
Faramarz Edalat, Juan C Camacho, Nima Kokabi, et al.
Cancer Treatment Reviews
|
March 18, 2023
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer
Jeremie Calais, Stephen M Eulau, Linda Gardner, et al.
Nuclear Medicine Communications
|
May 9, 2023
Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions
Shannon Fortin Ensign, Muskan Agarwal, Molly Klanderman, et al.
EJNMMI Research
|
March 15, 2026
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting
Emirhan Harbi, Gokce Belge Bilgin, Louise Emmett, et al.
Journal of Cardiac Failure
|
July 28, 2021
Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience
Mohamed Elwazir, Megan L Krause, John P Bois, et al.
The Prostate
|
October 11, 2021
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy
Masaya Jimbo, Jack R Andrews, Mohamed E Ahmed, et al.
The Prostate
|
September 12, 2022
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis
Jamal Alamiri, Cameron J Britton, Mohamed E Ahmed, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
Phillip H Kuo, Don C Yoo, Ryan Avery, et al.
The Prostate
|
June 2, 2022
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
Alex J Liu, Heidi E Kosiorek, Benjamin E Ueberroth, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Clinical Nuclear Medicine
|
August 15, 2017
PET/CT in an 8-Year-Old Girl With Epstein-Barr Virus-Associated Smooth Muscle Tumor
Ishan Garg, Maria J Baladron Zanetti, Saba Yasir, et al.
Clinical Nuclear Medicine
|
October 9, 2015
Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver
Faramarz Edalat, Juan C Camacho, Nima Kokabi, et al.
Cancer Treatment Reviews
|
March 18, 2023
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer
Jeremie Calais, Stephen M Eulau, Linda Gardner, et al.
Nuclear Medicine Communications
|
May 9, 2023
Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions
Shannon Fortin Ensign, Muskan Agarwal, Molly Klanderman, et al.
EJNMMI Research
|
March 15, 2026
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting
Emirhan Harbi, Gokce Belge Bilgin, Louise Emmett, et al.
Journal of Cardiac Failure
|
July 28, 2021
Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience
Mohamed Elwazir, Megan L Krause, John P Bois, et al.
The Prostate
|
October 11, 2021
Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy
Masaya Jimbo, Jack R Andrews, Mohamed E Ahmed, et al.
The Prostate
|
September 12, 2022
Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis
Jamal Alamiri, Cameron J Britton, Mohamed E Ahmed, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
Phillip H Kuo, Don C Yoo, Ryan Avery, et al.
The Prostate
|
June 2, 2022
The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases
Alex J Liu, Heidi E Kosiorek, Benjamin E Ueberroth, et al.
Page
of 3